GlassScriptPhysician profile
David Dai Dang
NPI 1932162385
$32,257.67
in general payments reported to CMS, 2019-2025
25 companies · $5,855 in 2025
The $5,855 reported for 2025 was more than what 87% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,845 · 2020: $2,939 · 2021: $4,381 · 2022: $4,637 · 2023: $5,545 · 2024: $6,057 · 2025: $5,855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Education: $88.60 · Travel and Lodging: $9.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,358.90 |
| Education | $88.60 |
| Travel and Lodging | $9.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $8,501.82 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $8,035.09 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $3,456.87 | 2019-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $2,354.73 | 2020-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $2,095.37 | 2019-2025 | Taltz, Zepbound |
| Genzyme Corporation | $1,776.66 | 2019-2025 | |
| Pfizer INC. | $1,521.86 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $814.27 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $719.41 | 2019-2025 | Ofev, Cyltezo |
| Aimmune Therapeutics, INC. | $589.69 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $561.35 | 2021-2023 | |
| Celgene Corporation | $373.07 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $303.62 | 2019-2025 | Orencia |
| Fresenius Kabi USA, LLC | $273.73 | 2023-2025 | Idacio |
| Ani Pharmaceuticals, INC. | $183.34 | 2024-2025 | Purified Cortrophin Gel |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $136.54 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $109.98 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $109.13 | 2021-2025 | Saphnelo |
| Janssen Scientific Affairs, LLC | $106.78 | 2022 | |
| Genentech USA, INC. | $67.87 | 2022-2023 | Actemra |
| Aurinia Pharma U.S., INC. | $52.18 | 2022 | |
| Vivus LLC | $35.34 | 2022 | |
| Hikma Pharmaceuticals USA | $35.05 | 2019-2020 | |
| Radius Health, INC. | $26.61 | 2025 | Tymlos |
| Medexus Pharma, INC. | $17.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.